Epigenetic Regulation of BDNF in Major Depression
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The investigators will (1) detect the associations between BDNF DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive patients, (2) check the correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and (3) discuss the possible mechanisms of epigenetic regulation of BDNF in Taiwanese major depressive patients.
Condition |
---|
Major Depressive Disorder |
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
Official Title: | Epigenetic Regulation of Brain-Derived Neurotropic Factor in Patients With Major Depression |
- BDNF DNA methylation, histone modification, blood BDNF protein and RNA and BDNF rs6265 gene [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- the associations between BDNF DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive patients; the correlation between blood BDNF protein and RNA and BDNF rs6265 gene [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
Blood
Estimated Enrollment: | 160 |
Study Start Date: | August 2010 |
Estimated Study Completion Date: | July 2013 |
Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Major depressive patients |
Healthy subjects |
Detailed Description:
BDNF (brain-derived neurotrophic factor) had been chosen as a candidate gene for a development of major depression. BDNF had been reported to have an important role on neuronal plasticity, axonal growth and connectivity, and participating in the local response to various types of neuronal stressors. BDNF also influences the differentiation of neurons.
In the past studies, the investigators had found that major depressive women had lower serum BDNF protein levels than healthy controls, and their BDNF levels became significantly increased after antidepressant treatments. In addition, some authors had found that reduced expression of BDNF was noted in postmortem brain of completed suicide subjects. Suicidal major depressive patients also had lower plasma BDNF levels than non-suicidal major depressive patients. These findings suggested that BDNF might play an important role in the suicidal behavior.
However, in past studies, the results did not fully explain why major depressive patients with same genotypes had different clinical expression, including the severity of depression, with/without suicide, and the treatment response. Recently, some papers found that there were relationships between epigenetic regulation, including DNA methylation and histone modification, and psychopathology of major depression. Therefore, we try to investigate the relationships between epigenetic regulation of BDNF and major depression.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
This 2-year study will be conducted in our clinical setting. By a semi-structured interview for DSM-IV criteria, a total of 160 subjectes (80 healthy controls and 80 patients with major depression) will be recruited in this study. In the first year (recruiting 40 healthy controls and 40 patients with major depression), the data of BDNF DNA methylation in all subjects will be collected. In the second year (recruiting another 40 healthy controls and 40 patients with major depression), the data of BDNF histone modification in all subjects will be collected and the mechanism of epigenetic regulation of BDNF in major depression will be discussed.
Inclusion Criteria:
The clinical screening and assessment in patients with major depression:
- 40 major depression will be recruited in psychiatric inpatients according to DSM-IV criteria by a semi-structured interview. The assessment will be done by two senior psychiatrists. The intra-rater and inter-rater reliability will be done before this project started.
- The patients had the ability to complete the written inform consent.
- The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.
- The 17-item Hamilton Depression Rating Scale (HAM-D) was used to assess severity of depression. The minimum baseline score of the 17-item HAM-D was 18.
Exclusion Criteria:
- The patients had systemic diseases, including metabolic, heart, and liver diseases。
- The patients had received any drugs before entering this protocol.
- The patients were heavy smokers or dependent on alcohol.
- The use of secondary generation anti-psychotic drugs and mood stabilizers.
Contact: Tiao-Lai Huang, M.D. | 886-7-7317123 ext 8753 | a540520@adm.cgmh.org.tw |
Taiwan | |
Department of Psychiatry, Chang Gung Memorial Hospital | Recruiting |
Kaohsiung, Taiwan, 833 | |
Contact: Tiao-Lai Huang, M.D. 886-7-7317123 ext 8753 a540520@adm.cgmh.org.tw | |
Principal Investigator: Tiao-Lai Huang, M.D. |
Principal Investigator: | Tiao-Lai Huang, M.D. | Chang-Gung Memorial Hospital, Kaohsiung |
No publications provided
Responsible Party: | Tiao-Lai Huang, Head of Department of Psychiatry, Chang Gung Memorial Hospital |
ClinicalTrials.gov Identifier: | NCT01182103 History of Changes |
Other Study ID Numbers: | NSC99-2628-B-182-002-MY2 |
Study First Received: | August 11, 2010 |
Last Updated: | November 22, 2011 |
Health Authority: | Taiwan: Department of Health |
Keywords provided by Chang Gung Memorial Hospital:
Major depression BDNF DNA methylation Histone modification |
Additional relevant MeSH terms:
Depression Depressive Disorder Depressive Disorder, Major |
Behavioral Symptoms Mood Disorders Mental Disorders |
ClinicalTrials.gov processed this record on October 17, 2012